For the quarter ending 2025-09-30, RCUS has $974M in assets. $238M in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 238 | 248 | ||
| Marketable securities | 593 | 663 | ||
| Receivable from collaboration partners ( and 6 from a related party) | 11 | 15 | ||
| Prepaid expenses and other current assets | 15 | 20 | ||
| Total current assets | 857 | 946 | ||
| Long-term marketable securities | 10 | 16 | ||
| Property and equipment, net | 42 | 44 | ||
| Other noncurrent assets | 65 | 69 | ||
| Total assets | 974 | 1,075 | ||
| Accounts payable (29 and to a related party) | 42 | 29 | ||
| Deferred revenue (52 and 85 to a related party) | 52 | 71 | ||
| Other current liabilities | 141 | 110 | ||
| Total current liabilities | 235 | 210 | ||
| Deferred revenue, noncurrent (53 and 234 to a related party) | 53 | 60 | ||
| Long-term debt | 98 | 97 | ||
| Other noncurrent liabilities | 152 | 159 | ||
| Common stock and additional paid-in capital 0.0001 par value per share 400.0 shares authorized 107.1 shares in 2025 and 92.2 shares in 2024 issued and outstanding | 1,815 | 1,793 | ||
| Accumulated deficit | -1,379 | -1,244 | ||
| Total stockholders equity | 436 | 549 | ||
| Total liabilities and stockholders equity | 974 | 1,075 | ||
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)